Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2008-11-06
2011-12-27
Carlson, Karen (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C530S300000, C530S350000
Reexamination Certificate
active
08084413
ABSTRACT:
A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2α or β. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
REFERENCES:
patent: 5869450 (1999-02-01), Wei et al.
patent: 5959109 (1999-09-01), Whitten et al.
patent: 6147275 (2000-11-01), Vale et al.
patent: 6353152 (2002-03-01), Lee et al.
patent: 6812210 (2004-11-01), Vale et al.
patent: 6838274 (2005-01-01), Vale, Jr. et al.
patent: 6953838 (2005-10-01), Vale et al.
patent: 7291341 (2007-11-01), Hsu et al.
patent: 2002/0082409 (2002-06-01), Hsu et al.
patent: 2004/0034882 (2004-02-01), Vale et al.
patent: WO 97/00063 (1997-01-01), None
patent: WO 99/51261 (1999-10-01), None
patent: WO 02/34934 (2002-05-01), None
U.S. Appl. No. 09/714,692, filed Nov. 16, 2000, Lee and Mar.
Brar et al., “Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart,”Endocrinology, 145:24-35, 2004.
Brunner et al., “Molecular cloning and characterization of the Fugu rubripes MEST/COPG2 imprinting cluster and chromosomal localization in Fugu and Tetradon nigroviridis,”Chromosome Research, 8(6):465-476, 2000.
Chen et al., “Design and synthesis of a series of non-peptide high-affinity human corticotrophin-releasing factor 1 receptor antagonists,”J. Med. Chem., 39:4358-4360, 1996.
Christos et al., “Corticotropin-releasing factor receptor antagonists,”Expert Opinion on Therapeutic Patents, 8(2):143-152, 1998.
Eckart et al., “Actiosn of CRF and its analogs,”Current Medicinal Chemsitry, 6:1035-1053, 1999.
Hsu et al., “Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor,”Nature Medicine, 7(5):605-611, 2001.
Lewis et al., “Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor,”Proc. Natl. Acad Sci. USA, 98:7570-7575, 2001.
Li et al., “Urocortin III-immunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression,”J. Neurosci., 22(3):991-1001, 2002.
Martinez et al., “Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2,”J. Pharmacology Exp. Thera., 301:611-617, 2002.
Martinez et al., “Urocortins and the regulation of gastrointestinal motor function and visceral pain,”Peptides, 25:1733-1744, 2004.
National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AW293249, Jan. 16, 2000.
Office Communication issued in Canadian Application No. 2,425,902, dated May 23, 2008.
Office Communication issued in Israeli Application No. 154553, dated Feb. 24, 2008.
Office Communication issued in Japanese Patent Application No. 2002-573033, dated Feb. 19, 2008.
Office Communication, issued in U.S. Appl. No. 10/099,766, dated Apr. 8, 2004.
Office Communication, issued in U.S. Appl. No. 10/099,766, dated Nov. 5, 2003.
Office Communication, issued in U.S. Appl. No. 10/771,224, dated Feb. 16, 2005.
Office Communication, issued in U.S. Appl. No. 11/214,371, dated Feb. 1, 2007.
Office Communication, issued in U.S. Appl. No. 11/214,371, dated Apr. 26, 2007.
Office Communication, issued in U.S. Appl. No. 11/214,371, dated Aug. 1, 2008.
Office Communication, issued in U.S. Appl. No. 11/214,371, dated Apr. 18, 2006.
Office Communication, issued in U.S. Appl. No. 11/214,371, dated Oct. 20, 2005.
Perrin et al., “A soluble form of the first extracellular domain of mouse type 2beta corticotropin-releasing factor receptor reveals differential ligand specificity,”J. Biol. Chem., 278:155595-15600, 2003.
Reyes et al., “Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors,”PNAS, 98(5):2843-2848, 2001.
Rühmann et al., “Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): Development of CRF2β-selective antisauvagine-30,”Proc. Natl. Sci. USA, 95:15264-15269, 1998.
Schulz et al., “CP-154,526: A potent and selective non-peptide high-affinity antagonist of corticotrophin releasing factor receptors,”PNAS, 93:10477-10482, 1996.
Skelton et al., “The neurobiology of urocortin,”Regulatory Peptides, 93(1-3):85-92, 2000.
Supplementary European Search Report issued in European Application No. 02753685.3, dated Sep. 19, 2005.
Valdez et al., “Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist,”Brain Res., 80:206-212, 2003.
Office Communication, issued in Russian Patent Application No. 2007110981/10(011938), dated Dec. 27, 2011. (English translation).
Office Communication, issued in Canadian Patent Application No. 2,425,902, dated May 4, 2011.
Gulyas Jozsef
Kunitake Koichi S.
Lewis Kathy A.
Perrin Marilyn H.
Rivier Jean E.
Carlson Karen
Fulbright & Jaworski L.L.P.
Research Development Foundation
LandOfFree
Urocortin-III and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Urocortin-III and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Urocortin-III and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4308852